183 related articles for article (PubMed ID: 30646226)
1. Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.
Zhang Y; Zhang M; Chen M; Mei J; Xu L; Guo R; Lin X; Li J; Peng Z
JAMA Netw Open; 2018 Oct; 1(6):e183213. PubMed ID: 30646226
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of the Initial and Best Responses after Chemoembolization in the Treatment of Intermediate-Stage Hepatocellular Carcinoma with Preserved Liver Function.
Park C; Chu HH; Kim JH; Kim SY; Alrashidi I; Gwon DI; Yoon HK; Kim N
J Vasc Interv Radiol; 2020 Dec; 31(12):1998-2006.e1. PubMed ID: 32988715
[TBL] [Abstract][Full Text] [Related]
3. Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?
Chen S; Peng Z; Zhang Y; Chen M; Li J; Guo R; Li J; Li B; Mei J; Feng S; Kuang M
Radiology; 2021 Mar; 298(3):680-692. PubMed ID: 33464183
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.
Pinter M; Ulbrich G; Sieghart W; Kölblinger C; Reiberger T; Li S; Ferlitsch A; Müller C; Lammer J; Peck-Radosavljevic M
Radiology; 2015 Dec; 277(3):903-12. PubMed ID: 26131911
[TBL] [Abstract][Full Text] [Related]
5. Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis.
Massani M; Stecca T; Ruffolo C; Bassi N
Updates Surg; 2017 Mar; 69(1):67-73. PubMed ID: 28097502
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Combined Therapy Using Conventional Chemoembolization and Radiofrequency Ablation Versus Conventional Chemoembolization for Ultrasound-Invisible Early-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Cancer Stage 0 or A).
Lee H; Yoon CJ; Seong NJ; Jeong SH; Kim JW
Korean J Radiol; 2018; 19(6):1130-1139. PubMed ID: 30386144
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
Wen P; Chen SD; Wang JR; Zeng YH
Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
[TBL] [Abstract][Full Text] [Related]
8. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
[TBL] [Abstract][Full Text] [Related]
9. Impact of cone-beam computed tomography with automated feeder detection software on the survival outcome of patients with hepatocellular carcinoma during treatment with conventional transarterial chemoembolization.
Bannangkoon K; Hongsakul K; Tubtawee T
BMC Gastroenterol; 2021 Nov; 21(1):419. PubMed ID: 34749658
[TBL] [Abstract][Full Text] [Related]
10. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
[TBL] [Abstract][Full Text] [Related]
11. Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma.
Cheung AH; Lam CS; Tam HS; Cheung TT; Pang R; Poon RT
Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):493-498. PubMed ID: 27733318
[TBL] [Abstract][Full Text] [Related]
12. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma.
Kim BK; Kim SU; Kim KA; Chung YE; Kim MJ; Park MS; Park JY; Kim DY; Ahn SH; Kim MD; Park SI; Won JY; Lee DY; Han KH
J Hepatol; 2015 Jun; 62(6):1304-10. PubMed ID: 25637785
[TBL] [Abstract][Full Text] [Related]
13. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
14. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
[TBL] [Abstract][Full Text] [Related]
15. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
[TBL] [Abstract][Full Text] [Related]
16. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Hepatocellular Carcinoma Treated with Conventional Transcatheter Arterial Chemoembolization: A Propensity Score Matched Analysis.
Deng Z; Zhang W; Peng J; Gao L; Zhang C; Lei K; Gong J; Xiong B
Cardiovasc Intervent Radiol; 2024 May; 47(5):592-603. PubMed ID: 38605220
[TBL] [Abstract][Full Text] [Related]
17. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.
Salem R; Gordon AC; Mouli S; Hickey R; Kallini J; Gabr A; Mulcahy MF; Baker T; Abecassis M; Miller FH; Yaghmai V; Sato K; Desai K; Thornburg B; Benson AB; Rademaker A; Ganger D; Kulik L; Lewandowski RJ
Gastroenterology; 2016 Dec; 151(6):1155-1163.e2. PubMed ID: 27575820
[TBL] [Abstract][Full Text] [Related]
18. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma.
Hao MZ; Lin HL; Chen QZ; Hu YB; Chen JB; Zheng JX; Zhou D; Zhang H
J Dig Dis; 2017 Jan; 18(1):31-39. PubMed ID: 27987344
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience.
Zhou J; Liu Y; Ren Z; Zhang Y; Zhang M
J Cancer Res Ther; 2017; 13(5):767-772. PubMed ID: 29237901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
